Advances in systemic chemotherapy and immunotherapy for metastatic colorectal cancer

Nikhil Grandhi; Bindiya Patel; Olivia Aranha

doi:10.1016/j.scrs.2023.100972

Advances in systemic chemotherapy and immunotherapy for metastatic colorectal cancer

Nikhil Grandhi, Bindiya Patel, Olivia Aranha

Research output: Contribution to journal › Review article › peer-review

Abstract

Colorectal cancer is the second leading cause of cancer related death in the United States. Approximately 25% of patients are diagnosed with metastatic colorectal cancer (mCRC) and the 5-year survival rate in mCRC is low at 14%. Primary treatment for mCRC is systemic therapy, which includes chemotherapy, immunotherapy, and targeted agents. With advances in genomic profiling, we can now tailor treatment to unique patient populations and improve overall survival. In this review, we discuss treatment strategies for mCRC patients based on tumor sidedness, KRAS/BRAF wild-type versus mutant tumors, and review the benefit of immunotherapy in microsatellite unstable and mismatch repair deficient tumors.

Original language	English
Article number	100972
Journal	Seminars in Colon and Rectal Surgery
Volume	34
Issue number	3
DOIs	https://doi.org/10.1016/j.scrs.2023.100972
State	Published - Sep 2023

Keywords

Chemotherapy
Colorectal cancer
Genomic profiling
Immunotherapy
Mutant KRAS/BRAF

Access to Document

10.1016/j.scrs.2023.100972

Cite this

@article{31fe417f923e4ac7b386388af9873aae,

title = "Advances in systemic chemotherapy and immunotherapy for metastatic colorectal cancer",

abstract = "Colorectal cancer is the second leading cause of cancer related death in the United States. Approximately 25% of patients are diagnosed with metastatic colorectal cancer (mCRC) and the 5-year survival rate in mCRC is low at 14%. Primary treatment for mCRC is systemic therapy, which includes chemotherapy, immunotherapy, and targeted agents. With advances in genomic profiling, we can now tailor treatment to unique patient populations and improve overall survival. In this review, we discuss treatment strategies for mCRC patients based on tumor sidedness, KRAS/BRAF wild-type versus mutant tumors, and review the benefit of immunotherapy in microsatellite unstable and mismatch repair deficient tumors.",

keywords = "Chemotherapy, Colorectal cancer, Genomic profiling, Immunotherapy, Mutant KRAS/BRAF",

author = "Nikhil Grandhi and Bindiya Patel and Olivia Aranha",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = sep,

doi = "10.1016/j.scrs.2023.100972",

language = "English",

volume = "34",

journal = "Seminars in Colon and Rectal Surgery",

issn = "1043-1489",

number = "3",

}

TY - JOUR

T1 - Advances in systemic chemotherapy and immunotherapy for metastatic colorectal cancer

AU - Grandhi, Nikhil

AU - Patel, Bindiya

AU - Aranha, Olivia

PY - 2023/9

Y1 - 2023/9

N2 - Colorectal cancer is the second leading cause of cancer related death in the United States. Approximately 25% of patients are diagnosed with metastatic colorectal cancer (mCRC) and the 5-year survival rate in mCRC is low at 14%. Primary treatment for mCRC is systemic therapy, which includes chemotherapy, immunotherapy, and targeted agents. With advances in genomic profiling, we can now tailor treatment to unique patient populations and improve overall survival. In this review, we discuss treatment strategies for mCRC patients based on tumor sidedness, KRAS/BRAF wild-type versus mutant tumors, and review the benefit of immunotherapy in microsatellite unstable and mismatch repair deficient tumors.

AB - Colorectal cancer is the second leading cause of cancer related death in the United States. Approximately 25% of patients are diagnosed with metastatic colorectal cancer (mCRC) and the 5-year survival rate in mCRC is low at 14%. Primary treatment for mCRC is systemic therapy, which includes chemotherapy, immunotherapy, and targeted agents. With advances in genomic profiling, we can now tailor treatment to unique patient populations and improve overall survival. In this review, we discuss treatment strategies for mCRC patients based on tumor sidedness, KRAS/BRAF wild-type versus mutant tumors, and review the benefit of immunotherapy in microsatellite unstable and mismatch repair deficient tumors.

KW - Chemotherapy

KW - Colorectal cancer

KW - Genomic profiling

KW - Immunotherapy

KW - Mutant KRAS/BRAF

UR - http://www.scopus.com/inward/record.url?scp=85162848157&partnerID=8YFLogxK

U2 - 10.1016/j.scrs.2023.100972

DO - 10.1016/j.scrs.2023.100972

M3 - Review article

AN - SCOPUS:85162848157

SN - 1043-1489

VL - 34

JO - Seminars in Colon and Rectal Surgery

JF - Seminars in Colon and Rectal Surgery

IS - 3

M1 - 100972

ER -

Advances in systemic chemotherapy and immunotherapy for metastatic colorectal cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this